-
-
-
-
-
-
-
Tevogen expands COVID-19 T cell therapy to cover 65% of US population
-
-
-
-
-
-
-
Tevogen.AI expands Microsoft, Databricks ties for cancer model beta
-
-
-
-
-
-
-
Tevogen Bio (TVGN) expands TVGN 489 target population for patients 65+
-
-
-
-
-
-
-
Tevogen Bio (TVGN) files patent on T Cell vaccine
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Fo
-
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

